What It Is
Neuroxelin is not a single molecule — it is a commercial name for a pre-mixed blend of four separate research peptides, typically combined in one vial at fixed ratios: PE-22-28 (10 mg), Pinealon/EDR (10 mg), N-acetyl Semax (20 mg), and N-acetyl Selank (8 mg), for roughly 48 mg total.
Because "Neuroxelin" is a seller-chosen product name rather than a standardized chemical designation, different vendors can use the same name for different formulations. The ingredient list and certificate of analysis for any specific product should be checked directly rather than assumed from the name alone.
Component Breakdown
- PE-22-28 — a shortened synthetic analog of spadin ("mini-spadin"), studied in rodents as an inhibitor of the TREK-1 potassium channel, a mechanism explored in depression-related research.[14]
- Pinealon (EDR) — a three-amino-acid peptide (glutamate-aspartate-arginine) studied mainly in animal models for effects on oxidative stress, gene expression, and neuronal survival; discussed in the literature as a longer-horizon cellular-resilience peptide rather than an acute cognitive enhancer.[16]
- N-acetyl Semax — a chemically modified version of Semax, itself a synthetic ACTH fragment with a stabilizing tail, studied for effects on BDNF/TrkB neurotrophin signaling and cognitive performance in animal and limited clinical research.[20]
- N-acetyl Selank — a chemically modified version of Selank, a synthetic tuftsin analog with human and animal research in anxiety-related contexts, including a published comparison against a prescription anti-anxiety medication.[23]
How It Works
Each component targets a different biological pathway: an ion channel (PE-22-28), general cellular-stress and gene-expression pathways (Pinealon), neurotrophin signaling linked to learning (Semax), and GABA-related, anxiolytic-adjacent gene expression (Selank). That spread across mechanisms is the stated rationale for combining them into one multi-pathway formula, rather than any demonstrated synergy between the four.
The "N-acetyl" prefix on the Semax and Selank components refers to a chemical modification (N-terminal acetylation) intended to alter the stability of the parent peptide. It does not automatically mean a stronger or better effect, and evidence on how the modification changes the parent peptides' effects in humans is limited.
What the Research Shows
The evidence base behind Neuroxelin is real but fragmented and uneven across its four ingredients. Selank has some human clinical literature, including a published comparison with a prescription anxiolytic in generalized anxiety disorder.[23] Semax has decades of mechanistic and some clinical research on neurotrophin pathways. PE-22-28 and Pinealon are supported mainly by preclinical rodent and cell studies.
Critically, no published research has evaluated the four-ingredient Neuroxelin combination itself as a single product. Any claim about the blend's combined effects is an extrapolation from its separate ingredients, not a tested finding on the finished formula.
Safety & Side Effects
Because the blend itself has never been studied, there is no blend-specific safety or side-effect data. Each individual component's safety profile is also incompletely characterized in humans, and combining four active peptides introduces interaction possibilities that have not been formally assessed in any trial.
As with any compounded research-peptide product, purity, sterility, and dosing accuracy depend entirely on the individual manufacturer rather than on any regulatory review.
Regulatory Status
None of the four components in Neuroxelin — individually or combined — are FDA-approved drugs. Neuroxelin is sold and marketed explicitly as a research-use compound, not a medicine, and has no regulatory approval, standardized dose, or reviewed safety label in any jurisdiction.